The American Diabetes Association's 86th Scientific Sessions is shaping up to be a landmark moment for obesity and diabetes medicine. Eli Lilly has announced it will present new clinical data on retatrutide, Mounjaro (tirzepatide), and Foundayo at the ADA meeting, offering the scientific community — and patients waiting on the frontlines — a deeper look at where this drug class is headed. For anyone tracking the retatrutide pipeline, this presentation represents a meaningful inflection point in the public evidence base.
Retatrutide — commonly referred to as reta in patient communities — is a once-weekly subcutaneous injection and a first-in-class triple agonist, simultaneously activating GLP-1, GIP, and glucagon receptors. That triple receptor mechanism, sometimes called triple G in online patient communities, distinguishes reta from existing GLP-1 and dual GIP/GLP-1 therapies. The glucagon receptor component adds meaningful metabolic activity, particularly around fat oxidation and energy expenditure, which is one reason the weight loss numbers from reta trials have consistently exceeded those seen with earlier agents.
According to Lilly's announcement, the ADA 86th Scientific Sessions presentation will include new analyses of retatrutide alongside data on Foundayo and Mounjaro, with the company framing this moment as part of building toward "a new era of choice in diabetes and obesity care." That framing matters clinically: these are not isolated drug updates, but rather a coordinated portfolio of agents targeting metabolic disease across a spectrum of severity and treatment need.
The retatrutide data being presented builds on a foundation already established in Phase 2 — where the 12mg dose achieved a mean weight loss of approximately 24.2% at 48 weeks in adults with obesity — and extends into Phase 3, where the TRIUMPH-4 trial recorded a mean weight loss of 28.7% at 68 weeks, the highest ever reported in a Phase 3 obesity trial. Full peer-reviewed Phase 3 publication remains pending as of April 2026, and no NDA has been filed with the FDA as of that date, meaning ADA 2026 may offer the most comprehensive public presentation of this data to date.
While retatrutide commands significant attention in obesity medicine, the ADA 2026 presentation from Lilly also encompasses pivotal Phase 3 findings from the ACHIEVE program evaluating Foundayo, Lilly's oral GLP-1 receptor agonist for type 2 diabetes.
The Phase 3 ACHIEVE results demonstrated that Foundayo outperformed both oral semaglutide and dapagliflozin in type 2 diabetes management. A clinically important distinction for Foundayo is its dosing flexibility: unlike oral semaglutide, which requires administration under strict fasting conditions with a limited water intake window, Foundayo can be taken without food or water restrictions. That tolerability and convenience difference is not trivial — medication adherence in chronic disease management is directly tied to dosing burden, and a GLP-1 therapy that removes the rigid morning fasting protocol may prove meaningfully more accessible for a broad patient population.
New analyses from the ATTAIN program will also be presented at ADA 2026, further characterizing Foundayo's clinical profile. These presentations, taken together, signal Lilly's intent to establish a full-spectrum cardiometabolic portfolio spanning injectable and oral delivery, dual and triple receptor mechanisms, and applications across both obesity and type 2 diabetes.
The table below contextualizes where retatrutide sits relative to other major weight loss agents based on available Phase 2 and Phase 3 trial data:
| Agent | Mechanism | Trial / Phase | Duration | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 agonist | STEP-1 / Phase 3 | 68 weeks | ~14.9% |
| Tirzepatide 15mg | GLP-1 / GIP dual agonist | SURMOUNT-1 / Phase 3 | 72 weeks | ~20.9% |
| Retatrutide 12mg | GLP-1 / GIP / glucagon triple agonist | Phase 2 (NEJM 2023) | 48 weeks | ~24.2% |
| Retatrutide 12mg | GLP-1 / GIP / glucagon triple agonist | TRIUMPH-4 / Phase 3 | 68 weeks | ~28.7% |
These figures underscore the dose-dependent and mechanism-dependent progression in efficacy across drug classes. In the Phase 2 retatrutide trial published in the New England Journal of Medicine (Jastreboff et al., 2023), 100% of participants in the 8mg arm achieved at least 5% weight loss at 48 weeks, while 48% of those in the 12mg arm achieved 25% or greater weight loss. The lipid improvements were equally notable: triglycerides fell by up to 34% at 12mg, and LDL cholesterol decreased by 15–17% across higher-dose arms at 24 weeks — changes with genuine cardiometabolic significance beyond weight alone.
Regarding tolerability, the most common adverse events in Phase 2 were gastrointestinal — nausea, diarrhea, and vomiting — which were dose-dependent and largely concentrated during the titration phase. A signal worth monitoring is dysesthesia, which occurred in 20.9% of participants at the 12mg dose in TRIUMPH-4 compared to 0.7% on placebo. The TRIUMPH-4 titration schedule was gradual — beginning at 2mg and escalating over four-week intervals to the 12mg maintenance dose — a protocol designed in part to improve tolerability and support dose completion. Even so, discontinuation rates at 12mg reached 18.2%, with some participants stopping due to what was characterized as perceived excessive weight loss.
For individuals who have been following retatrutide's development, the ADA 2026 presentations represent the most significant public update on the drug since the TRIUMPH-4 press release in December 2025. The convergence of Phase 3 weight loss data, new cardiometabolic analyses, and Lilly's broader portfolio narrative at a major scientific forum suggests that the regulatory and commercial pathway for retatrutide is continuing to advance — though as of April 2026, no NDA has been filed and no FDA approval timeline has been publicly confirmed.
What can be said clinically is this: the evidence trajectory for retatrutide is strong and consistent. From the 24.2% mean weight loss at 48 weeks in Phase 2 to the 28.7% at 68 weeks in TRIUMPH-4, reta has demonstrated effects on body weight, triglycerides, cholesterol, and quality of life that place it in a distinct category. The SF-36v2 quality-of-life scores improved across all active dose groups in Phase 2, a reminder that outcomes extend well beyond the number on a scale — they include energy, mobility, and the reduction in what many patients describe as food noise, the constant cognitive preoccupation with eating that makes sustained behavior change so difficult without pharmacological support.
The source for this ADA 2026 announcement can be reviewed directly at Lilly's investor relations page.
For anyone considering retatrutide as part of a future obesity treatment plan, now is the time to stay informed and stay positioned. glp3md.com maintains a waitlist for individuals interested in receiving updates on retatrutide access as the regulatory landscape evolves. Joining the waitlist does not guarantee access to medication, treatment, or a prescription — retatrutide is not FDA-approved, and no promises are made regarding availability or timelines. What the waitlist does offer is priority access to accurate, clinically grounded information as new data emerges, so that when the landscape does shift, those who are prepared can act with confidence.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.